![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GSK, UCB JAPAN TO JOINTLY PROMOTE IMURAN TABLETS
GSK, UCB JAPAN TO JOINTLY PROMOTE IMURAN TABLETS
June 27, 2005
On June 20, GlaxoSmithKline (GSK) and UCB Japan jointly announced that they have agreed to co-promote Imuran tablets, an immunosupressant manufactured and currently distributed by GSK, in Japan. The two companies will launch the joint promotion efforts on July 1. Imuran tablets, which are currently marketed in about 100 countries worldwide, are used in the treatment of transplant rejection.
Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=10375)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct